San Diego-based SynteractHCR, a full-service CRO, will unveil its Intelligent Clinical Development platform (ICD+) at the upcoming DIA annual meeting in Boston. 

SynteractHCR’s goal is to take time and cost out of the drug development process to deliver successful therapies to patients sooner. ICD+ is the platform by which the company leverages clinical development expertise, appropriate technology and optimized processes, tailored to each client’s needs, to drive solution-oriented efficiencies on a global scale. ICD+ allows sponsors to get to decision points faster, while providing a uniform approach to trials globally to promote consistent standards and high quality.

“As we strive to streamline clinical trials and deliver better therapies in healthcare, we are confident that with ICD+ we offer a great solution to our clients,” says SynteractHCR chief executive Wendel Barr.  

In March 2013, SynteractHCR was formed from the merger of Synteract and Harrison Clinical Research (HCR), and operates from 16 locations worldwide supporting phase I-IV trials.